Clinic Chat: Monkeypox
With Pharmacist Kishan
Quick Facts about Monkeypox
What is monkeypox?
It is a virus typically found close to tropical rainforests and is related to smallpox but is less transmissible with milder symptoms. However, the virus has still been spreading across the globe and in many communities.
How to get monkeypox?
It can be spread by close prolonged contact through inhaling saliva droplets, touching blisters or handling contaminated objects. Close contact with monkeypox is a risk factor.
Symptoms of monkeypox?
Monkeypox symptoms begin 5 to 21 days after being exposed and can include fever, fatigue, swollen lymph nodes, and body-wide blisters. Symptoms can range from minor to more severe. The blisters can potentially be quite painful with some people even needing stronger painkillers to manage their symptoms.
Imvamune is a vaccine approved in Canada for protection against monkeypox and smallpox, and it is currently available for free in Ontario. It can be used preventatively prior to exposure, or may be used right after a potential exposure to the virus has occurred. There are currently restrictions on who can access the vaccine at this time and the first dose is being prioritized to individuals who may be at higher risk.
Answers to common monkeypox questions
There is specific eligibility criteria for who can receive the vaccine at this time and more info is available here.
Be on the lookout for our announcements and updates on this page and our Instagram page (@theprepclinic).
The vaccine may cause mild to moderate side effects, with the most common being some soreness at the site of injection. Less commonly people may experience tiredness or headache. Unlike the COVID-19 vaccine it is not common to experience fever or feel run down for several days after. The vaccine is also not expected to cause a scar like older smallpox vaccination could.
People taking any version of PrEP can receive the monkeypox vaccine. The medication and vaccine are not expected to interact / affect each other.
The vaccine is approved to be given in 2 doses at 28 days apart, but Public Health guidance is to receive just the first dose at this time due to supply limitations.
The vaccine is still highly effective after the first dose with protection of approximately 85% after 28 days of receiving it. The second dose can be delayed in the series.
Due to limitations on supply, Public Health has recently expanded second doses only to the following who already met previous criteria plus the following:
- Individuals receiving dialysis, cancer therapy, recently
received a stem cell transplant, individuals who have received organ transplantation,
and people living with HIV with CD4 count ≤ 200/mm3 or a detectable viral load.
- Individuals on specific medications that can suppress the
immune system are also eligible – and this may include some people receiving
treatment for auto-immune and inflammatory conditions (eg. Crohn’s, Rheumatoid Arthritis).
To check if you are eligible contact our clinic.
- Monkeypox Vaccine (Imvamune) Guidance for Health Care Providers. Ontario Ministry of Health [updated June 14, 2022; cited July 26, 2022]. Available from: https://www.health.gov.on.ca/
en/pro/programs/emb/docs/ Monkeypox_Imvamune_Guidance_ HCP.pdf
- Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada. National Advisory Committee on Immunization (NACI) [updated June 2022; cited July 16, 2022]. Available from: https://www.canada.ca/content/
dam/phac-aspc/documents/ services/immunization/ national-advisory-committee- on-immunization-naci/guidance- imvamune-monkeypox/guidance- imvamune-monkeypox-en.pdf
- IMVAMUNE Product Monograph. Bavarian Nordic A/S. [updated November 5, 2020; cited July 26, 2022]. Available from: https://pdf.hres.ca/dpd_pm/